QIAGEN N.V.
535 articles about QIAGEN N.V.
-
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements
3/18/2024
QIAGEN announced a partnership with the International Panel Physicians Association to support and educate panel physicians around the globe on the latest tuberculosis screening requirements.
-
QIAGEN announces Form 20-F annual report filing for 2023 results
3/11/2024
QIAGEN N.V. announced that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission.
-
QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery
2/27/2024
QIAGEN announced the launch of QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries.
-
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification
2/15/2024
QIAGEN announced two significant achievements in sustainability through recognitions by My Green Lab, a non-profit organization dedicated to advancing sustainability in scientific research:
-
QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability
2/6/2024
QIAGEN N.V. announced results for the fourth quarter and full-year 2023.
-
QIAGEN announces partnership with Penn State University to advance microbiome sciences
1/25/2024
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.
-
QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million
1/18/2024
QIAGEN N.V. announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.
-
QIAGEN N.V. to release results for Q4 2023 and hold webcast
1/11/2024
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023.
-
QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems
1/8/2024
QIAGEN announced the U.S. Food and Drug Administration clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States.
-
QIAGEN announces plans to return approximately $300 million to shareholders
1/7/2024
QIAGEN N.V. announced a plan to return up to approximately $300 million to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split.
-
QIAGEN expands business in Middle East with new regional headquarters and major projects
1/3/2024
QIAGEN announced a significant expansion of its business in the Middle East region, which includes three major developments.
-
DNA Labs International solves significant cold cases with QIAGEN workflow for forensic genetic genealogy
11/30/2023
QIAGEN and DNA Labs International announced that DLI has recently solved two decades-old “cold cases” using QIAGEN solutions.
-
QIAGEN launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for improved sample processing and RNA isolation
11/15/2023
QIAGEN announced the expansion of its sample technologies portfolio with the introduction of two new products aimed at supporting researchers in managing diverse materials such as bone, tissue and soil samples.
-
QIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers
11/9/2023
QIAGEN announced the launch of three new kits for use on its QIAcuity systems and a major new software update designed to expand the portfolio of applications for use of digital PCR technology in areas like cell and gene therapies, DNA and RNA quantification, as well as food and pharmaceuticals safety:
-
QIAGEN launches complete Sample to Insight workflow for microbiome research
11/6/2023
QIAGEN announced the launch of the Microbiome WGS SeqSets, a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maximizes efficiency and reproducibility in microbiome research.
-
QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER
10/30/2023
QIAGEN announced results for the third quarter and first nine months of 2023.
-
QIAGEN N.V. to release results for Q3 2023 and hold webcast
10/9/2023
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023.
-
QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus
10/4/2023
QIAGEN announced the launch of its QuantiFERON-EBV RUO assay. Epstein-Barr virus, or human herpes virus 4, is estimated in various epidemiological studies to be positive in more than 90% of the world’s population and is a significant pathogen in organ transplant recipients.
-
QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
9/28/2023
QIAGEN announced the expansion of its clinical decision support software, QIAGEN Clinical Insight Interpret, to include artificial intelligence -enhanced coverage of thousands of rare disease genes, advancing its AI-capabilities that have been established for over two decades.
-
QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report
9/27/2023
QIAGEN announced the release of its Sustainability Report 2022, emphasizing its unwavering focus on driving positive change for society through its goals for Environment, Social and Governance metrics.